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Available online 19 December 2015Calciﬁc aortic valve disease is a slowly progressive disorder that ranges from mild valve thickening (i.e. aortic
sclerosis) to severe calciﬁcation of valves (i.e. aortic stenosis). Gene expression proﬁling analysis of non-
calciﬁed controls, sclerotic, and calciﬁed aortic valveswas performed to better understand the progression of cal-
ciﬁc aortic valve disease. The complementary information related to processing and statistical analysis of theDNA
microarray data is provided in this article. Interpretation of this data can be found in a research article entitled
“MicroRNA-125b and chemokine CCL4 expression are associatedwith calciﬁc aortic valve disease” [1]. Themicro-
array data complies with MIAME guidelines and is deposited in the Gene Expression Omnibus (GEO) database
under accession number GSE51472.
© 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ue samples
Human Genome
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valvular cups, converted to
Affymetrix arrays
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l, Oulu Finland1. Direct link to deposited data
All samples are separately available in GEO database under accession
number GSE51472 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE51472.
2. Experimental design, materials and methods
2.1. Materials
Aortic valves for this study were removed from patients undergoing
valve or aortic root surgery [1]. The study protocol complied with the
principles outlined in the Declaration of Helsinki, and it was approved
by the Research Ethics Committee of Oulu University Hospital,en access article under the CC BY-NCOulu, Finland. All operations were made following normal surgical pro-
cedures. After removal, aortic valve cusps were placed immediately in
liquid nitrogen and stored at−70 °C until analyzed [1–2].
Total RNA from ﬁve samples from each group (non-calciﬁed control,
ﬁbro(sclero)tic and stenotic valves) was extracted with the guanidine
thiocyanate-CsCl method [3–4] and further puriﬁed by RNeasy Midi Kit
(Qiagen) according to manufacturer's instructions. The quality and
integrity of the isolated total RNAweremonitored by gel electrophoresis.
2.2. DNA microarray analysis
The biotinylated cRNA probes were prepared and hybridized ac-
cording to the Affymetrix GeneChip Expression Analysis Technical
Manual. First, cDNA was reverse-transcripted from 5 μg of total
RNA with a T7-(dT)24-primer by using the One-cycle cDNA synthesis
kit (Affymetrix). The DNAwas puriﬁed using GeneChip Sample Cleanup
Module (Qiagen). The cRNAwas prepared and biotin-labeled by in vitro
transcription by using an IVT-labeling kit (Affymetrix), biotinylated
cRNA was cleaned with a GeneChip Sample Cleanup Module (Qiagen),
followed by fragmentation from 35 to 200 nt. Then, 10 μg of cRNA
was hybridized on Affymetrix GeneChip® Human Genome U133 Plus
2.0 Arrays for 16 h at 45 °C. After hybridization GeneChipswerewashed
and stained with streptavidin–phycoerythrin (Molecular Probes) in the
Affymetrix Fluidics Station 400. Staining signal was ampliﬁed by
biotinylated anti-streptavidin (Vector Laboratories) and second
staining with streptavidin–phycoerythrin by using Affymetrix Fluid-
ics station according to the standard protocol. GeneChip Scanner
3000 (Affymetrix) with GeneChip Operating Software (GCOS) v.
1.2 (Affymetrix) was used in scanning. Scanned images were processed
using Affymetrix Microarray Suite 5.0. The probe quality was evaluated
by the 3′/5′ hybridization ratio for the set of housekeeping genes on the-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
108 J. Rysä / Genomics Data 7 (2016) 107–108Affymetrix chip. The obtained ratio was b2 and comparable among all
hybridized samples.
2.3. Statistical analysis
The Affymetrix software GCOS was used to generate cell intensity
data ﬁles (CEL). The software programGeneSpring version 7.2 (Agilent)
was used for normalization, clustering, ﬁltering, and statistical analyses.
CEL ﬁles (from GCOS 1.2) were imported into GeneSpring using the
Robust Multi-Array Average normalization. All the samples were then
normalized to the median of the controls. Genes were deﬁned as
differentially expressed if the change was at least 2.0-fold and statis-
tically signiﬁcant (P b 0.05, one-way ANOVA and Benjamini and
Hochberg false discovery rate).
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